Budesonide orodispersible tablets are superior to maintain and even further improve quality of life in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

(1) Technische Universität München,München,Germany

(2) USZ Zürich,Zürich,Switzerland

(3) Hospital General de Tomelloso Dept. of Digestive Health,Tomelloso,Spain

(4) Coopertion of Internal Medicine Center for Digestive Diseases,Hamburg,Germany

(5) Hospital Universitario de La Princesa,Madrid,Spain

(6) Hospital 12 de Octubre Dept. de Gastroenterologia,Madrid,Spain

(7) Sana Klinikum Lichtenberg,Berlin,Germany

(8) CRH Clinic Siloah,Hannover,Germany

(9) Universitätsspital Basel,Basel,Switzerland

(10) St. George`s University Hospitals,London,United Kingdom

(11) Otto-Von Guericke University,Madgeburg,Germany

(12) Academisch Med. Centrum Amsterdam,Amsterdam,Netherlands

(13) Dr. Falk Pharma GmbH,Freiburg,Germany

(14) University Hospital (CHUV),Lausanne,Switzerland

(15) Durham University,Durham,United Kingdom

(16) Swiss EoE Research Network,Olten,Switzerland



This item was part of the Oesophageal, Gastric and Duodenal Disorders II (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019